Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis

NCT01480154 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01480154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01480154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 23, 2011
Completion date
March 31, 2027
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, stage iii cutaneous melanoma ajcc v7, stage iii prostate cancer ajcc v7, stage iii renal cell cancer ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, stage iv prostate cancer ajcc v7, stage iv renal cell cancer ajcc v7